Teaching Health Resilience in a Hospital Setting: A Peer-led Intervention (THRIVE)

February 24, 2026 updated by: University of Pennsylvania

Teaching Health Promotion and Resilience in Varied Environments: a Peer-led Intervention Following Hospital Discharge

The purpose of the study is to develop an acceptable, feasible, and effective peer-led bundle of health resilience and promotion services to be delivered in the hospital setting, called the THRIVE intervention.

The main question it aims to answer is: Will participants receiving the THRIVE intervention have a reduced risk of self-reported non-fatal overdoses OR skin/soft tissue infections compared to participants receiving enhanced usual care?

Researchers will compare the THRIVE model to enhanced usual care to see if the THRIVE model helps participants reduce their number of self-reported non-fatal overdoses OR skin/soft tissue infections.

Intervention participants will:

  • Receive one in-person session from a peer support specialist while in the hospital
  • Receive weekly text messages from the peer support specialist for a 12-week period
  • Receive monthly, multiple-choice assessments via text message at Month 1, 2, 3, 4, 5, and 6
  • Complete a baseline, 3-month, and 6-month assessment with Research Assistants

Enhanced usual care participants will:

  • Receive a handout with health resilience education and resources in their local area
  • Receive monthly, multiple-choice assessments via text message at Month 1, 2, 3, 4, 5, and 6
  • Complete a baseline, 3-month, and 6-month assessment with Research Assistants

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

390

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

  • Name: Research Program Coordinator
  • Phone Number: 412-679-9848
  • Email: thriving@pitt.edu

Study Locations

  • United States
    • Pennsylvania
      • Pittsburgh, Pennsylvania, United States, 15232
        • Not yet recruiting
        • UPMC Shadyside Hospital
        • Contact:
        • Principal Investigator:
          • Jane M Liebschutz, MD
      • Pittsburgh, Pennsylvania, United States, 15203
        • Not yet recruiting
        • UPMC Mercy Hospital
        • Contact:
        • Principal Investigator:
          • Jane M Liebschutz, MD
      • Pittsburgh, Pennsylvania, United States, 15213
        • Recruiting
        • UPMC Presbyterian-Montefiore Hospital
        • Contact:
        • Principal Investigator:
          • Jane M Liebschutz, MD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Participants who are: a) admitted to University of Pittsburgh Medical Center (UPMC) Shadyside Hospital, UPMC Presbyterian-Montefiore Hospital, UPMC Mercy Hospital for inpatient or observation status, or b) seen in the Emergency Department setting at UPMC Presbyterian-Montefiore Hospital and UPMC Mercy Hospital.
  • Participants must have a current diagnosis of Opioid Use Disorder based on the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) diagnostic criteria.
  • Participants must be at least 18 years of age on day of admission.
  • Participants must be able to speak and read English.

Exclusion Criteria:

  • Participants diagnosed with dementia and/or cognitive impairments.
  • Participants with acute psychiatric complications, such as schizophrenia with acute psychosis, acute mania, or suicidal ideation (which may impact the ability of a participant to consent and actively participate in treatment).
  • Participants who are pregnant or lactating at onset of study.
  • Participants who cannot read or speak English.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Other: Enhanced Usual Care
Other: Enhanced Usual Care
Participants will receive a handout that includes health resilience education and resources in their local area as part of enhanced usual care.
Experimental: Peer Intervention
Behavioral: Peer Intervention
Participants will receive one peer-led, in-person session boosted by weekly text messages over a 12-week period.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Effectiveness of the THRIVE intervention compared to enhanced usual care (EUC) at lowering the incidence of non-fatal overdoses OR skin and soft tissue infections
Time Frame: Baseline to 6 months
Cumulative incidence of non-fatal overdose OR skin and soft tissue infection
Baseline to 6 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Effectiveness of the THRIVE intervention compared to EUC at lowering the incidence of non-fatal overdoses
Time Frame: Baseline to 6 months
Cumulative incidence of non-fatal overdose
Baseline to 6 months
Effectiveness of the THRIVE intervention compared to EUC at lowering the incidence of skin and soft tissue infections
Time Frame: Baseline to 6 months
Cumulative incidence of skin and soft tissue infection
Baseline to 6 months

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Effectiveness of the THRIVE intervention on change in higher risk infection behaviors (characterized by BIRSI score) compared to EUC
Time Frame: Baseline to 6 months
Change in higher risk infection behaviors measured as the total score on the BIRSI
Baseline to 6 months
Heterogeneity of treatment effect by race (Black versus white) in the THRIVE intervention arm
Time Frame: Baseline to 6 months
Cumulative incidence of non-fatal overdose OR skin or soft tissue infection, by race (Black versus white)
Baseline to 6 months
Effectiveness of the THRIVE intervention on change in health resilience adoption compared to EUC (a)
Time Frame: Baseline to 6 months
(a) Change in the proportion of participants who self-report naloxone use in past 30 days to reverse another person's overdose
Baseline to 6 months
Effectiveness of the THRIVE intervention on change in health resilience adoption compared to EUC (b)
Time Frame: Baseline to 6 months
(b) Change in the proportion of participants who self-report currently carrying naloxone
Baseline to 6 months
Effectiveness of the THRIVE intervention on change in health resilience adoption compared to EUC (c)
Time Frame: Baseline to 6 months
(c) Change in the proportion of participants who self-report using at least one drug checking strategy in the past 30 days
Baseline to 6 months
Effectiveness of the THRIVE intervention on health resilience access compared to EUC (a)
Time Frame: Baseline to 6 months
(a) Change in the proportion of participants who self-report having received at least one of: naloxone, syringes, or new or unused pipes in past 30 days
Baseline to 6 months
Effectiveness of the THRIVE intervention on health resilience access compared to EUC (b)
Time Frame: Baseline to 6 months
(b) Change in the proportion of participants who self-report visiting a syringe services program in past 30 days
Baseline to 6 months
Effectiveness of the THRIVE intervention on health resilience access compared to EUC (c)
Time Frame: Baseline to 6 months
(c) Change in the proportion of participants who self-report receiving any health resilience services from a needle exchange facility in past 30 days
Baseline to 6 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University of Pennsylvania

Collaborators

National Institute on Drug Abuse (NIDA)
University of Pittsburgh

Investigators

  • Principal Investigator: Jacqueline D Wilson, MD, University of Pennsylvania

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

February 18, 2025

Primary Completion (Estimated)

April 1, 2028

Study Completion (Estimated)

August 1, 2028

Study Registration Dates

First Submitted

January 13, 2025

First Submitted That Met QC Criteria

February 20, 2025

First Posted (Actual)

February 24, 2025

Study Record Updates

Last Update Posted (Actual)

February 27, 2026

Last Update Submitted That Met QC Criteria

February 24, 2026

Last Verified

February 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 857581
  • 1R01DA057633 (U.S. NIH Grant/Contract)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Health Promotion

Clinical Trials on Peer Intervention

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Egypt

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe